Skip to main content
. 2024 Feb 29;36(1):78–89. doi: 10.21147/j.issn.1000-9604.2024.01.08

Table 4. Co-expression of CLDN18.2, HER2 and PD-L1.

Characteristics n (%)
CLDN18.2 ≥2+, 40% CLDN18.2 ≥2+, 70%
CLDN18.2, claudin 18 isoform 2; HER2, epidermal growth factor receptor 2; PD-L1, programmed death-ligand 1; pos, positive; CPS, combined positive score.
HER2-pos 20 (4.0) 15 (3.0)
PD-L1-pos
 CPS≥1 97 (19.8) 84 (17.2)
 CPS≥5 61 (12.5) 52 (10.7)
 CPS≥10 38 (7.8) 31 (6.4)